95% CI: 0.321.00), though no significant effect was found on all-cause mortality (HR 0.81
Throughout the study timeframe, 961 participants using GLP-1RAs developed depression, and 902 participants using SGLT2is developed depression
, The most recent published research (January 2025), a large nationwide case-time-control study using data in France, found no evidence that GLP-1 use increased short-term risk of suicide or suicide attempt in patients with obesity or history of psychiatric disorders
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-duo 1)
Instead of pointing fingers, its better to be productive and look for solutions